Which has higher valuation and earnings, MEDP or CHE?

Medpace has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.75 $451.12M $17.06 35.89 Chemed $2.53B 2.60 $265.24M $19.91 25.27

Is MEDP or CHE more profitable?

Medpace has a net margin of 17.67% compared to Chemed's net margin of 10.60%. Medpace's return on equity of 110.15% beat Chemed's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% Chemed 10.60% 31.77% 18.90%

Does the media prefer MEDP or CHE?

In the previous week, Medpace had 4 more articles in the media than Chemed. MarketBeat recorded 11 mentions for Medpace and 7 mentions for Chemed. Medpace's average media sentiment score of 0.85 beat Chemed's score of 0.33 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, CHE or DGX?

Quest Diagnostics has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.60 $265.24M $19.91 25.27 Quest Diagnostics $11.04B 2.47 $992M $9.42 26.18

Is CHE or DGX more profitable?

Chemed has a net margin of 10.60% compared to Quest Diagnostics' net margin of 9.18%. Chemed's return on equity of 31.77% beat Quest Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% Quest Diagnostics 9.18% 16.01% 7.27%

Does the media refer more to CHE or DGX?

In the previous week, Quest Diagnostics had 4 more articles in the media than Chemed. MarketBeat recorded 11 mentions for Quest Diagnostics and 7 mentions for Chemed. Quest Diagnostics' average media sentiment score of 0.69 beat Chemed's score of 0.33 indicating that Quest Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Quest Diagnostics 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, CHE or LH?

Labcorp has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.60 $265.24M $19.91 25.27 Labcorp $13.95B 1.86 $876.50M $12.09 26.49

Is CHE or LH more profitable?

Chemed has a net margin of 10.60% compared to Labcorp's net margin of 6.99%. Chemed's return on equity of 31.77% beat Labcorp's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% Labcorp 6.99% 16.74% 7.81%

Does the media favor CHE or LH?

In the previous week, Chemed had 2 more articles in the media than Labcorp. MarketBeat recorded 7 mentions for Chemed and 5 mentions for Labcorp. Labcorp's average media sentiment score of 0.58 beat Chemed's score of 0.33 indicating that Labcorp is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Labcorp 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, CHE or GH?

Chemed has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.60 $265.24M $19.91 25.27 Guardant Health $982.02M 24.51 -$416.28M -$3.49 N/A

Is CHE or GH more profitable?

Chemed has a net margin of 10.60% compared to Guardant Health's net margin of -38.33%. Chemed's return on equity of 31.77% beat Guardant Health's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% Guardant Health -38.33% N/A -25.40%

Does the media prefer CHE or GH?

In the previous week, Guardant Health had 16 more articles in the media than Chemed. MarketBeat recorded 23 mentions for Guardant Health and 7 mentions for Chemed. Chemed's average media sentiment score of 0.33 beat Guardant Health's score of 0.18 indicating that Chemed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Guardant Health 7 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to FMS or CHE?

In the previous week, Chemed had 6 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 7 mentions for Chemed and 1 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 1.44 beat Chemed's score of 0.33 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fresenius Medical Care AG & Co. KGaA 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Chemed (CHE) Competitors

$503.12 -2.85 (-0.56%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$515.02 +11.89 (+2.36%)

As of 09/18/2026 07:57 PM Eastern

Compare

CHE vs. MEDP, DGX, LH, GH, and FMS

Should you buy Chemed stock or one of its competitors? Chemed's main competitors and comparable companies include Medpace (MEDP), Quest Diagnostics (DGX), Labcorp (LH), Guardant Health (GH), and Fresenius Medical Care AG & Co. KGaA (FMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Chemed compare to Medpace?

Medpace (NASDAQ:MEDP) and Chemed (NYSE:CHE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Medpace currently has a consensus price target of $595.20, indicating a potential downside of 2.80%. Chemed has a consensus price target of $530.75, indicating a potential upside of 5.49%. Given Chemed's higher probable upside, analysts clearly believe Chemed is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Medpace has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.75	$451.12M	$17.06	35.89
Chemed	$2.53B	2.60	$265.24M	$19.91	25.27

Medpace has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Chemed has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Medpace has a net margin of 17.67% compared to Chemed's net margin of 10.60%. Medpace's return on equity of 110.15% beat Chemed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Chemed	10.60%	31.77%	18.90%

In the previous week, Medpace had 4 more articles in the media than Chemed. MarketBeat recorded 11 mentions for Medpace and 7 mentions for Chemed. Medpace's average media sentiment score of 0.85 beat Chemed's score of 0.33 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.0% of Medpace shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 20.5% of Medpace shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Medpace beats Chemed on 13 of the 16 factors compared between the two stocks.

How does Chemed compare to Quest Diagnostics?

Chemed (NYSE:CHE) and Quest Diagnostics (NYSE:DGX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Chemed has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Chemed has a net margin of 10.60% compared to Quest Diagnostics' net margin of 9.18%. Chemed's return on equity of 31.77% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
Quest Diagnostics	9.18%	16.01%	7.27%

In the previous week, Quest Diagnostics had 4 more articles in the media than Chemed. MarketBeat recorded 11 mentions for Quest Diagnostics and 7 mentions for Chemed. Quest Diagnostics' average media sentiment score of 0.69 beat Chemed's score of 0.33 indicating that Quest Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quest Diagnostics	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.60	$265.24M	$19.91	25.27
Quest Diagnostics	$11.04B	2.47	$992M	$9.42	26.18

Chemed pays an annual dividend of $2.80 per share and has a dividend yield of 0.6%. Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.4%. Chemed pays out 14.1% of its earnings in the form of a dividend. Quest Diagnostics pays out 36.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Chemed has increased its dividend for 16 consecutive years and Quest Diagnostics has increased its dividend for 14 consecutive years.

95.9% of Chemed shares are held by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are held by institutional investors. 3.3% of Chemed shares are held by company insiders. Comparatively, 0.9% of Quest Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Chemed presently has a consensus target price of $530.75, indicating a potential upside of 5.49%. Quest Diagnostics has a consensus target price of $236.31, indicating a potential downside of 4.19%. Given Chemed's higher probable upside, equities research analysts plainly believe Chemed is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54

Summary

Chemed and Quest Diagnostics tied by winning 10 of the 20 factors compared between the two stocks.

How does Chemed compare to Labcorp?

Chemed (NYSE:CHE) and Labcorp (NYSE:LH) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Chemed has a net margin of 10.60% compared to Labcorp's net margin of 6.99%. Chemed's return on equity of 31.77% beat Labcorp's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
Labcorp	6.99%	16.74%	7.81%

In the previous week, Chemed had 2 more articles in the media than Labcorp. MarketBeat recorded 7 mentions for Chemed and 5 mentions for Labcorp. Labcorp's average media sentiment score of 0.58 beat Chemed's score of 0.33 indicating that Labcorp is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Labcorp	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Chemed pays an annual dividend of $2.80 per share and has a dividend yield of 0.6%. Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 0.9%. Chemed pays out 14.1% of its earnings in the form of a dividend. Labcorp pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Chemed has increased its dividend for 16 consecutive years.

Chemed presently has a consensus target price of $530.75, indicating a potential upside of 5.49%. Labcorp has a consensus target price of $336.36, indicating a potential upside of 5.01%. Given Chemed's higher possible upside, analysts clearly believe Chemed is more favorable than Labcorp.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Labcorp	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

Labcorp has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.60	$265.24M	$19.91	25.27
Labcorp	$13.95B	1.86	$876.50M	$12.09	26.49

95.9% of Chemed shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 3.3% of Chemed shares are held by company insiders. Comparatively, 0.8% of Labcorp shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Chemed has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Summary

Chemed beats Labcorp on 10 of the 19 factors compared between the two stocks.

How does Chemed compare to Guardant Health?

Chemed (NYSE:CHE) and Guardant Health (NASDAQ:GH) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Chemed has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Guardant Health has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

95.9% of Chemed shares are owned by institutional investors. Comparatively, 92.6% of Guardant Health shares are owned by institutional investors. 3.3% of Chemed shares are owned by company insiders. Comparatively, 5.6% of Guardant Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Chemed has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.60	$265.24M	$19.91	25.27
Guardant Health	$982.02M	24.51	-$416.28M	-$3.49	N/A

Chemed currently has a consensus target price of $530.75, indicating a potential upside of 5.49%. Guardant Health has a consensus target price of $188.13, indicating a potential upside of 4.88%. Given Chemed's higher probable upside, research analysts plainly believe Chemed is more favorable than Guardant Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Guardant Health	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.96

Chemed has a net margin of 10.60% compared to Guardant Health's net margin of -38.33%. Chemed's return on equity of 31.77% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
Guardant Health	-38.33%	N/A	-25.40%

In the previous week, Guardant Health had 16 more articles in the media than Chemed. MarketBeat recorded 23 mentions for Guardant Health and 7 mentions for Chemed. Chemed's average media sentiment score of 0.33 beat Guardant Health's score of 0.18 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Guardant Health	7 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Chemed beats Guardant Health on 10 of the 17 factors compared between the two stocks.

How does Chemed compare to Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Chemed (NYSE:CHE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Fresenius Medical Care AG & Co. KGaA currently has a consensus target price of $23.57, suggesting a potential upside of 6.13%. Chemed has a consensus target price of $530.75, suggesting a potential upside of 5.49%. Given Fresenius Medical Care AG & Co. KGaA's higher possible upside, analysts clearly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresenius Medical Care AG & Co. KGaA	5 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.55
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Fresenius Medical Care AG & Co. KGaA pays an annual dividend of $0.61 per share and has a dividend yield of 2.7%. Chemed pays an annual dividend of $2.80 per share and has a dividend yield of 0.6%. Fresenius Medical Care AG & Co. KGaA pays out 31.6% of its earnings in the form of a dividend. Chemed pays out 14.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Chemed has raised its dividend for 16 consecutive years.

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Chemed. Fresenius Medical Care AG & Co. KGaA is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA	$22.20B	0.54	$1.11B	$1.93	11.51
Chemed	$2.53B	2.60	$265.24M	$19.91	25.27

8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 3.3% of Chemed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Chemed had 6 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 7 mentions for Chemed and 1 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 1.44 beat Chemed's score of 0.33 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fresenius Medical Care AG & Co. KGaA	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Chemed has a net margin of 10.60% compared to Fresenius Medical Care AG & Co. KGaA's net margin of 4.83%. Chemed's return on equity of 31.77% beat Fresenius Medical Care AG & Co. KGaA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fresenius Medical Care AG & Co. KGaA	4.83%	9.28%	4.16%
Chemed	10.60%	31.77%	18.90%

Fresenius Medical Care AG & Co. KGaA has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Chemed has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Summary

Chemed beats Fresenius Medical Care AG & Co. KGaA on 13 of the 19 factors compared between the two stocks.

Get Chemed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHE vs. The Competition

Export

Metric	Chemed	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$6.59B	$9.75B	$7.24B	$23.10B
Dividend Yield	0.56%	2.62%	2.57%	3.62%
P/E Ratio	25.27	34.09	275.49	28.21
Price / Sales	2.60	4.98	646.01	20.34
Price / Cash	20.44	121.76	76.25	36.36
Price / Book	7.28	5.30	10.46	4.67
Net Income	$265.24M	$313.45M	$3.49B	$1.07B
7 Day Performance	-2.34%	1.65%	0.59%	-1.64%
1 Month Performance	-5.95%	-0.85%	-1.74%	-3.60%
1 Year Performance	11.27%	16.30%	18.13%	8.41%

Chemed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHE Chemed	4.049 of 5 stars	$503.12 -0.6%	$530.75 +5.5%	+11.3%	$6.59B	$2.53B	25.27	15,811	News Coverage Analyst Downgrade High Trading Volume
MEDP Medpace	2.6193 of 5 stars	$595.41 +1.3%	$595.20 0.0%	+22.8%	$16.40B	$2.53B	34.90	6,200	Insider Trade
DGX Quest Diagnostics	4.0646 of 5 stars	$237.78 +1.2%	$236.31 -0.6%	+34.3%	$25.94B	$11.04B	25.24	57,000
LH Labcorp	3.6426 of 5 stars	$315.26 +1.2%	$336.36 +6.7%	+15.6%	$25.27B	$13.95B	26.08	71,000
GH Guardant Health	2.0357 of 5 stars	$167.84 +6.6%	$188.13 +12.1%	+203.3%	$21.12B	$1.18B	N/A	2,506	Trending News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CHE) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemed (CHE) Competitors

CHE vs. MEDP, DGX, LH, GH, and FMS

How does Chemed compare to Medpace?

Summary

How does Chemed compare to Quest Diagnostics?

Summary

How does Chemed compare to Labcorp?

Summary

How does Chemed compare to Guardant Health?

Summary

How does Chemed compare to Fresenius Medical Care AG & Co. KGaA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHE vs. The Competition

Chemed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Chemed (CHE) Competitors

CHE vs. MEDP, DGX, LH, GH, and FMS

How does Chemed compare to Medpace?

Do analysts recommend MEDP or CHE?

Which has higher valuation and earnings, MEDP or CHE?

Which has more risk & volatility, MEDP or CHE?

Is MEDP or CHE more profitable?

Does the media prefer MEDP or CHE?

Do insiders and institutionals believe in MEDP or CHE?

Summary

How does Chemed compare to Quest Diagnostics?

Which has more volatility & risk, CHE or DGX?

Is CHE or DGX more profitable?

Does the media refer more to CHE or DGX?

Which has higher valuation and earnings, CHE or DGX?

Is CHE or DGX a better dividend stock?

Do institutionals and insiders believe in CHE or DGX?

Do analysts prefer CHE or DGX?

Summary

How does Chemed compare to Labcorp?

Is CHE or LH more profitable?

Does the media favor CHE or LH?

Is CHE or LH a better dividend stock?

Do analysts prefer CHE or LH?

Which has stronger valuation & earnings, CHE or LH?

Do institutionals & insiders have more ownership in CHE or LH?

Which has more risk and volatility, CHE or LH?

Summary

How does Chemed compare to Guardant Health?

Which has more risk and volatility, CHE or GH?

Do institutionals and insiders believe in CHE or GH?

Which has stronger earnings and valuation, CHE or GH?

Do analysts prefer CHE or GH?

Is CHE or GH more profitable?

Does the media prefer CHE or GH?

Summary

How does Chemed compare to Fresenius Medical Care AG & Co. KGaA?

Do analysts recommend FMS or CHE?

Is FMS or CHE a better dividend stock?

Which has preferable valuation and earnings, FMS or CHE?

Do institutionals and insiders hold more shares of FMS or CHE?

Does the media refer more to FMS or CHE?

Is FMS or CHE more profitable?

Which has more risk & volatility, FMS or CHE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHE vs. The Competition

Chemed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools